Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2022

View Archived Issues

LIPA targeting with ERX-41 shown useful to treat TNBC

Genentech describes von Hippel-Lindau disease tumor suppressor inhibitors

New cytokine inhibitors patented by Peptinov SAS, Conservatoire National des Arts et Metiers

New HSD17B13 inhibitors discovered at Inipharm

Neuron23 divulges LRRK2/NUAK1/TYK2 inhibitors

New Bruton tyrosine kinase inhibitors identified at Biogen

TPI1 as a novel therapeutic target in breast cancer

Heme oxygenase-1-modified exosomes developed for temozolomide-resistant glioblastoma

Molecule "superglues" itself to enzyme to fight all stages of malaria parasite

Novel fungal Hsp90 inhibitors for the treatment of azole-resistant candidiasis

BioVaxys reports progress in pan-sarbecovirus vaccine program

Analysis of pain insensitivity disorder reveals new target for pain relief

Karolinska Development invests in PharmNovo to advance neuropathic pain treatment

Genuv and Nanocarry partner to treat metastatic tumors in the brain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...